In this guide

On this page

PFAS/2023/06 - Annex A

Table 4

PFAS/2023/06 Annex A

Last updated: 30 September 2025

View as PDF

In this guide

On this page

This is a paper for discussion. This does not represent the views of the Committee and should not be cited.

Table 4. Acute toxicity studies for PFCAs – PFNA

*Derived by contractor; ** calculated according to EFSA. (2012); NR – not reported; NA – not applicable.

Substance / CAS no. / purity / reference

Strain & species / sex / no. of animals

Dose (mg/kg bw/day) / vehicle / route of admin / duration / Guideline (GL) study / Good Laboratory Practice (GLP) status

PFAS concentration (µg/mL / µg/g)

Observed effects at LOAEL (controls vs treated groups).

Recovery (controls vs treated groups).

Published NOAEL / LOAEL (mg/kg bw)

Study author conclusions

Comments

PFNA

CAS No. not given

97%.

Das et al. (2017)

SV129 mice (wild type and PPAR-α null)

Male,

4/dose.

0 or 10 m/kg bw/day

Deionized water.

Gavage.

7 days.

Non-GL study.

GLP not stated.

NR

Males:

↑ absolute and relative liver weight (data only reported in figures).

↑ lipid and TGs in liver (data only reported in figures).

Recovery not assessed.

Males:

NA / 10

 

 

PFNA cause steatosis and increases in TG in the PPAR-α null mice indicating that the mechanism of the steatosis is at least partially PPAR-α independent.

K2

The study investigated whether structurally-diverse PFAS increase liver TG levels and cause steatosis and investigate mechanisms involved.

Only 4 male animals were used.

Study was funded by US Environmental Protection Agency.
View entire guide
Print guide